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naaa2@cam.ac.ukAbstractCentral congenital hypothyroidism (CCH) may occur in isolation, or more frequently in
combination with additional pituitary hormone deficits with or without associated
extrapituitary abnormalities. Although uncommon, it may be more prevalent than
previously thought, affecting up to 1:16 000 neonates in the Netherlands. Since TSH is not
elevated, CCH will evade diagnosis in primary, TSH-based, CH screening programs and
delayed detection may result in neurodevelopmental delay due to untreated neonatal
hypothyroidism. Alternatively, coexisting growth hormones or ACTH deficiency may pose
additional risks, such as life threatening hypoglycaemia. Genetic ascertainment is possible in
a minority of cases and reveals mutations in genes controlling the TSH biosynthetic pathway
(TSHB, TRHR, IGSF1) in isolated TSH deficiency, or early (HESX1, LHX3, LHX4, SOX3, OTX2) or
late (PROP1, POU1F1) pituitary transcription factors in combined hormone deficits. Since TSH
cannot be used as an indicator of euthyroidism, adequacy of treatment can be difficult to
monitor due to a paucity of alternative biomarkers. This review will summarize the normal
physiology of pituitary development and the hypothalamic–pituitary–thyroid axis, then
describe known genetic causes of isolated central hypothyroidism and combined pituitary
hormone deficits associated with TSH deficiency. Difficulties in diagnosis and management
of these conditions will then be discussed.Key Words
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.0 UJournal of Endocrinology
(2015) 227, R51–R71IntroductionCentral congenital hypothyroidism (CCH) is a rare
disorder in which inadequate thyroid hormone biosyn-
thesis occurs due to defective stimulation of a normal
thyroid gland by thyroid stimulating hormone (TSH). The
underlying molecular basis is often undefined, but
hypothalamic or pituitary pathology contributes to a
qualitative or quantitative deficit in TSH synthesis or
secretion (Persani 2012). In a minority of cases, TSH
deficiency is isolated and may occur as a result of defects
in genes controlling the TSH biosynthetic pathway, eg
mutations in the thyrotropin-releasing hormone receptor(TRHR), thyroid stimulating hormone b subunit (TSHB)
and the more recently-described immunoglobulin super-
family member 1 gene (IGSF1) (Garcia et al. 2014).
Alternatively, as normal pituitary development depends
on the sequential temporal and spatial expression of a
cascade of signaling molecules and transcription factors,
mutations in early (HESX1, LHX3, LHX4, SOX3, OTX2) or
late (PROP1, POU1F1) transcription factors may cause
central hypothyroidism with or without associated extra-
pituitary abnormalities. However, in these cases, central
hypothyroidism does not occur in isolation, but is one ofsed under a Creative Commons
nported License.
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227 :3 R52the evolving pituitary hormone deficiencies (Alatzoglou &
Dattani 2009, Kelberman et al. 2009).
Since TSH is not elevated in CCH, this entity will
evade diagnosis in TSH-based, primary CH screening
programs, and patients are at risk of neurodevelopmental
delay if severe CCH remains untreated postnatally.
Additionally, the delayed diagnosis of other pituitary
hormone deficiencies (Adrenocorticotrophic hormone;
ACTH, growth hormone; GH) may pose significant risks,
such as life threatening hypoglycaemia.
In spite of current knowledge regarding genetic causes
of CCH, the majority of cases do not have an identifiable
molecular defect in known causative genes. This review
will summarize our current understanding of the molecu-
lar genetics underlying CCH as well as highlighting
controversies in treatment and diagnosis.Physiology/embryology
Morphogenesis and cellular differentiation in
pituitary development
The development of the anterior pituitary requires the
sequential temporal and spatial expression of a cascade of
signaling molecules and transcription factors that are
important for organ commitment, cell proliferation,
patterning and terminal differentiation. Human pituitary
gland development in humans largely mirrors that in
rodents (Sheng & Westphal 1999) (Fig. 1). The anterior
pituitary develops from the hypophyseal placode that
appears ventrally in the midline of the anterior neural
ridge at embryonic day (E) 7.5, and is in continuity with
the future hypothalamo-infundibular region, which is
located in the rostral part of the neural plate (Rizzoti &
Lovell-Badge 2005). By E8.5 the placode appears as a
thickening of the roof of the primitive oral cavity and at
E9.0, it invaginates to form the rudimentary Rathke’s
pouch, from which the anterior and intermediate lobes
of the anterior pituitary are derived (Takuma et al. 1998,
Rizzoti & Lovell-Badge 2005). The definitive pouch is
formed by E10.5, whilst the neural ectoderm at the base of
the developing diencephalon evaginates to give rise to
the posterior pituitary. The pouch epithelium continues to
proliferate between E10.5 and E12 and separates from the
underlying oral ectoderm at E12.5. The progenitors of the
hormone-secreting cell types proliferate ventrally from
the pouch between E12.5 and 17.5 to populate the future
anterior lobe (Ward et al. 2005). Progenitor cells divide
around the lumen of Rathke’s pouch and relocate
ventrally as they differentiate. This ventral relocalisationhttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0341
 2015 The authors
Printed in Great Britainis associated with exit from the cell cycle (Drouin et al.
2010) and expression of cyclin-dependent kinase
inhibitor 1C (p57Kip2) and cyclin E, at the boundary
between the lumen and the forming anterior lobe
(Bilodeau et al. 2009).
In the developing pituitary, there are two populations
of thyrotrope cells: a transient population of rostral tip
thyrotropes and the ‘definitive’ thyrotropes that will
populate the anterior pituitary. The earliest marker of
differentiation in the anterior pituitary is the expression
by E11.5 of aGSU (alpha-glycoprotein subunit; Cga) in a
restricted patch of cells in the ventral region of Rathke’s
pouch. These aGSU positive cells will express the
transcription factor Islet-1 (Isl1) and will differentiate at
E12.5 by initiating the expression of thyroid stimulating
hormone subunit-b (Tshb) (Ericson et al. 1998, Kelberman
et al. 2009). This cell population, referred to as rostral tip
thyrotropes, is POU1F1-independent and will disappear at
birth (Himes & Raetzman 2009). The definitive thyro-
tropes are detected later, at E14.5, after the appearance of
corticotropes (that start to differentiate at E12.5), as
defined by the expression of Pomc (Zhu et al. 2007,
Kelberman et al. 2009). This cell population, referred to
as ‘thyrotropes’, is POU1F1-dependent and will secrete
functional TSH. In the adult pituitary gland, there are no
rostral tip thyrotropes and the expression of aGSU will
only be detected in thyrotropes and gonadotropes (Ericson
et al. 1998, Himes & Raetzman 2009, Kelberman et al.
2009). The expression of GH and Prolactin (Prl) by E15.5
is the hallmark of the differentiation of somatotrope
and lactotrope lineages respectively. Whilst gonadotropes
are the last cell type to emerge, beginning at E16.5 with
the onset of luteinizing hormone (LH) subunit b (Lhb)
expression, followed by follicle-stimulating hormone
(FSH) subunit b (Fshb) a day later (Kelberman et al. 2009).
Although the classic description of cell differentiation
is based on the sequential appearance of differentiating
markers, recent birthdating studies imply that endocrine
cells may be specified earlier and migrate some distance
before they can be characterized by their differentiated
markers. In fact, most of the hormone expressing cell types
appear to differentiate between E11.5 and E13.5, denoting
a broader range of specification rather than a sequential
pattern of discrete times (Davis et al. 2011).
Concomitantly with these events, the hypothalamic
primordium becomes morphologically evident in the
neural ectoderm at E9.5 with neurogenesis commencing
at E10, coinciding with the highest level of expression
of genes important for the regional patterning of
hypothalamic progenitor cells, such as Sim1, Sim2, ArxPublished by Bioscientifica Ltd
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Figure 1
Schematic representation of the stages of pituitary development in
rodents: (a) Oral ectoderm (b) Rudimentary pouch (c) Definitive pouch (d)
Adult pituitary gland. The close contact between the developing Rathke’s
pouch (red) and the infundibulum (yellow) is maintained throughout and
is important for the normal morphogenesis of the gland. I, infundibulum;
NP, neural plate; N, notochord; PP, pituitary placode; OM, oral membrane;
H, heart; F, forebrain; MB, midbrain; HB, hindbrain; RP, Rathke’s pouch; AN,
anterior neural pore; O, oral cavity; PL, posterior lobe; OC, optic chiasm;
P, pontine flexure; PO, pons; IL, intermediate lobe; AL, anterior lobe; DI,
diencephalon; SC, sphenoid cartilage. Reprinted from Trends in Genetics,
volume 15, Sheng HZ, Westphal H, Early steps in pituitary organogenesis,
pages 236–240, Copyright (1999), with permission from Elsevier.
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227 :3 R53and Nr5a1 (Shimogori et al. 2010). Hypothalamic neuro-
genesis is complete by E16 although expression of
hypothalamic terminal differentiation markers peak post-
natally (Shimogori et al. 2010). In the developing murine
hypothalamus, transcription factors including Gsh1,
Mash1, Ash1, Sim1, Sim2, Arnt2, Brn-2, and Otp are
important for the differentiation of the parvocellular
neurons secreting the neuropeptides TRH, thyrotropin-
releasing hormone; GHRH, growth-hormone releasing
hormone; SST, somatostatin; CRH, corticotropin-releasing
hormone (Shimogori et al. 2010, Diaz et al. 2015). In the
developing rat, hypothalamus Trh cells first appear at
E10.5 in the ventral part of the anterior paraventricular
area (VPa) and by E12.5 they are also found in the ventral
portion of the paraventricular hypothalamic complex
(TPVa) as well as in the central and dorsal portion of the
peduncular paraventricular area (CPa and DPa) (Diaz et al.
2015). Recently, Trh expressing cells were also detected in
the lateral hypothalamic area that is associated with
behavioural response to motivation and metabolic stimuli
(Horjales-Araujo et al. 2014).Genetic factors important for thyrotrope development
Signalling molecules from the ventral diencephalon
(Bmp4, Fgf8, Fgf4, Nkx2.1, Wnt5a), the oral ectoderm
(Sonic Hedgehog, Shh), the surrounding mesenchyme
(Bmp2, Chordin) and the pouch itself (Bmp2, Wnt4)http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0341
 2015 The authors
Printed in Great Britaincontribute to establish signalling gradients and the
expression of transcription factors which will determine
the positional identity of ventral pituitary cells (Zhu et al.
2007, Kelberman et al. 2009) (Fig. 2). Terminal differen-
tiation of the anterior pituitary cell types is the result of
complex interactions between extrinsic signalling
molecules and transcription factors (HESX1, SOX2, SOX3,
OTX2, LHX3, LXH4, GATA2, ISL1, PROP1, POU1F1) of
which GATA2, PITX1/2, PROP1 and POU1F1 are most
critical for the differentiation of thyrotropes.
Expression of Pitx1 is first detected in the anterior
ectoderm at E8.0, then expressed throughout the oral
ectoderm and in Rathke’s pouch by E 9.5, and main-
tained throughout anterior pituitary development in all
hormone-producing cell types. In the adult pituitary,
Pitx1 expression is highest in thyrotropes expressing aGSU
and in gonadotropes with lower levels in other hormone-
producing cell types (Lanctot et al. 1999). Pitx1 null
embryos have normal pituitary morphogenesis; however,
at birth the number of thyrotropes and gonadotropes are
reduced. This absence of early defects may in part be
explained by the redundant function of the closely related
PITX2.
Expression of PITX2 is detected widely in Rathke’s
pouch and in the developing pituirary, whilst in adults
it is expressed predominantly in thyrotropes and gonado-
tropes. Mice with targeted deletion of Pitx2 in thyrotropes
have smaller thyroid glands, upregulated levels ofPublished by Bioscientifica Ltd
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Figure 2
Schematic cascade of transcription factors and signaling molecule during
pituitary development. Terminal differentiation of the anterior pituitary
cell types is the result of complex interactions between extrinsic signalling
molecules and transcription factors (HESX1, SOX2, SOX3, OTX2, LHX3,
LXH4, GATA2, ISL1, PROP1, POU1F1). Possible pituitary phenotypes arising
from mutations at different stages of pituitary development are indicated.
SOD, septo-optic dysplasia; CNS, central nervous system; EPP, ectopic
posterior pituitary; CPHD, combined pituitary hormone deficiency. Repro-
duced, with permission, from Kelberman D, Rizzoti K, Lovell-Badge R,
Robinson IC, Dattani MT 2009 Genetic regulation of pituitary gland
development in human and mouse, Endocrine Reviews 30 790–829.
Copyright (2009) The Endocrine Society.
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227 :3 R54pituitary Pitx1 transcripts and circulating TSH and T4 in
the normal range (Castinetti et al. 2011). In these animals,
induction of hypothyroidism (by low iodine diet and oral
propylthiouracil) results in a blunted TSH response.
Although under these conditions control mice have
significant increase in PITX1 transcripts, they remain
unchanged in mutant animals (Castinetti et al. 2011).
Expression of Gata2 is first detected at E10.5 in the
ventral Rathke’s pouch, where it is induced by BMP2 along
with aGSU, therefore marking the prospective and
definitive thyrotropes and gonadotropes; its expression is
maintained in the adult pituitary. In vitro GATA2 activates
the Cga promoter and acts synergistically with POU1F1 to
induce expression of Tshb (Gordon et al. 2002). Ectopic
expression of Gata2 under the control of the Pou1f1http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0341
 2015 The authors
Printed in Great Britainpromoter results in dorsal expansion of the gonadotrope
population at the expense of the Pou1f1 lineage (somato-
tropes, lactotropes and thyrotropes). Therefore, GATA2
may be required for the specification of gonadotropes and
thyrotropes both in opposition and in synergy with
POU1F1 (Dasen et al. 1999).
Knock-out of GATA2 specifically in the pituitary
results in mice with fewer thyrotropes at birth, that
exhibit growth delay postnatally and produce less TSH in
response to severe hypothyroidism, compared to WT
animals. The population of thyrotropes is only transiently
reduced in neonates. However, in adult animals, levels of
circulating TSH remain low and the function of thyro-
tropes is abnormal. These Gata2-deficient mice have
increased levels of Gata3 transcripts in the pituitaryPublished by Bioscientifica Ltd
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227 :3 R55gland, suggesting that the upregulation of GATA3 may
have a compensatory role (Charles et al. 2006)
PROP1 (Prophet of PIT-1) is a pituitary-specific paired-
like homeodomain transcription factor initially detected
in the dorsal portion of Rathke’s pouch at E10-10.5; its
expression peaks at E12 and becomes undetectable by
E15.5 dpc (Kelberman et al. 2009). The onset of Prop1
expression is required for the emergence of the Pou1f1
lineage (somatotropes, lactotropes and thyrotropes),
whilst its persistent expression delays the differentiation
of gonadotropes (Cushman et al. 2001). In vitro PROP1 and
b-catenin form a complex, along with other cofactors that
directly repress Hesx1 while activating expression of
Pou1f1 (Olson et al. 2006)
The Ames dwarf mouse, that has a naturally occurring
Prop1 mutation resulting in an eight-fold reduction in
DNA-binding activity, has severe proportional dwarfism
and infertility with GH, TSH and PRL deficiency, and
reduced gonadotropin expression correlating with low
plasma LH and FSH. The anterior pituitary gland in these
animals is reduced in size by about 50% with an abnormal
looping appearance (Ward et al. 2005, Ward et al. 2006).
Pou1f1 is expressed relatively late during pituitary
development and is detectable in prospective somato-
tropes, lactotropes, and thyrotropes from E13.5. It reaches
maximum expression in differentiating GH, PRL, and TSH
cells by E16 and its extression persists in adulthood
(Kelberman et al. 2009). POU1F1 is required for the
production of GH, PRL, and TSHB as well as the expression
of GHRHR. Two naturally occurring recessive mouse
mutants, the Snell and Jackson dwarf mouse, exhibit an
identical phenotype with postnatal, but not embryonic,
anterior pituitary hypoplasia and GH, TSH, and PRL
deficiencies (Kelberman et al. 2009). POU1F1 is able to
inhibit GATA2, independently of its DNA binding proper-
ties, to prevent gonadotrope fate, whereas in thyrotropes,
POU1F1 and GATA2 act synergistically to promote the
thyrotrope fate (Dasen et al. 1999).Control of TSH biosynthesis
The hypothalamic–pituitary–thyroid axis
Positive regulation of thyroid hormone synthesis Cir-
culating concentrations of T3 and T4 are maintained
within a narrow range in vivo by a highly regulated balance
of positive and negative feedback mediated by the
hypothalamic–pituitary–thyroid (HPT) axis and centrally
regulated by TRH (Fig. 3). TRH is synthesized as a
prohormone in the paraventricular nucleus (PVN) of thehttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0341
 2015 The authors
Printed in Great Britainhypothalamus and matures into the TRH tripeptide amide
(pGlu-His-ProNH2) following post-translational cleavage
by prohormone convertases PC1/3 and 2. After axonal
transport to the median eminence, TRH reaches the
thyrotrophs of the anterior pituitary gland via the
hypothalamic portal vein, where it binds its G-protein
coupled receptor, TRHR, and activates a Gq/11 dependent
pathway involving mobilization of intracellular calcium
and activation of protein kinase C, culminating in TSH
synthesis and secretion. Pyroglutamyl peptidase II (PPII)
activity subsequently mediates degradation of extracellu-
lar TRH (Hinkle et al. 2012, Fekete & Lechan 2014). Recent
data suggests a role for the membrane glycoprotein IGSF1
in normal TRHR expression, although the precise function
of IGSF1 remains unclear (Sun et al. 2012).
Besides upregulating transcription of the TSH alpha
(aGSU) and b subunit genes (CGA and TSHB), TRH
mediates conjugation of TSH a and b subunits and
regulates glycosylation and secretion of heterodimeric
TSH. Incorporation of oligosaccharide determines TSH
bioactivity, which is principally defined by the type and
conformation of carbohydrate chain added at Asn-76 and
-102 of the a subunit and Asn-43 on the b subunit such
that TSH with a high sialic acid content exhibits decreased
bioactivity and increased half life. (Persani 1988, Estrada
et al. 2014).
In the thyroid, TSH binds a G-protein coupled
receptor, TSH-receptor (TSHR), stimulating follicular cell
growth and thyroid hormone synthesis and release,
predominantly in the form of the prohormone thyroxine
(T4). Deiodination of T4 in peripheral tissues yields the
active hormone, 3,5,3 0-triodothyronine (T3) which binds
thyroid hormone receptors (TR’s) to exert its transcrip-
tional effects. TR isoforms TRa1, b1, and b2 exhibit tissue-
specific expression patterns and heterodimerize with
retinoid X receptor (RXR) on specific Thyroid Receptor
DNA response elements (TREs), usually located in
promoter regions of target genes. With upregulated
genes, unliganded TRs mediate repression of basal gene
transcription by binding the TRE together with other
proteins, eg corepressors (NCOR1 and SMRT) and histone
deacetylases (HDAC3) (Cheng et al. 2010). T3 binding
results in a conformational change of the receptor ligand-
binding domain, leading to coactivator recruitment,
histone acetylation, relaxation of chromatin and tran-
scriptional activation (Ortiga-Carvalho et al. 2014).
Negative regulation of thyroid hormone synthesis A
classical negative feedback loop maintains circulating
thyroid hormone levels within the normal range and isPublished by Bioscientifica Ltd
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Diagramatic representation of the hypothalamic–pituitary–thyroid axis
with positive regulation (black) predominantly mediated by thyrotropin-
releasing hormone (TRH) and negative (grey) feedback influences,
predominantly mediated by thyroid hormone receptor (TR) isoforms b2
and b1. Putative transporter molecules (grey) mediating these effects are
annotated. OATP1C1 is expressed in capillaries throughout the brain,
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(reviewed in Fliers et al. (2006)). Tissue-specific TR isoform expression
is described, for thyroid hormone target tissues.
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thalamus, thyroid hormone is taken up into the brain
from cerebrospinal fluid (CSF) in the 3rd ventricle or from
blood vessels in the median eminence by deiodinase type
2 (DIO2)-expressing tanycytes or astrocytes respectively.
DIO2, converts T4 to T3 which then enters the TRH
neurons and binds nuclear TR’s. Intracellular delivery of
thyroid hormones requires active transport, likely to be
mediated by monocarboxylate transporter eight (MCT8)
for uptake from tanycytes into neuronal cells and by
organic anion-transporting polypeptide 1c1 (OATP1C1)
for transport across the blood-brain barrier (Alkemade
et al. 2011, Garcia et al. 2014, Alkemade 2015). A shorter
T3-mediated negative feedback loop operates in the
anterior pituitary, with the transport mechanism for
pituitary thyroid hormone uptake remaining poorly
defined. TSHR expression has also been demonstrated inhttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0341
 2015 The authors
Printed in Great Britainpituitary folliculostellate cells, leading to the suggestion
that paracrine signaling in the pituitary may also
contribute to negative feedback, but the mechanisms
underlying this remain speculative (Prummel et al. 2004,
Garcia et al. 2014).
In the hypothalamus, thyroid hormones downregulate
transcription of the pro-TRH and PC1/3 and PC2 genes
(Hollenberg et al. 1995, Perello et al. 2006) resulting in
reduced levels of mature TRH. In the anterior pituitary,
transcription ofCGA and TSHB genes is inhibited (Shupnik
et al. 1985, Wondisford et al. 1989, Wang et al. 2009). The
mechanisms for negative regulation of transcription by TRs
remain poorly understood (Ortiga-Carvalho et al. 2014) but
may involve recruitment of corepressors instead of coacti-
vators, eg Ncor1 during transcriptional repression of
murine Cga, (You et al. 2010) Trans-repression, where
liganded TR’s interact with and inhibit the activity of otherPublished by Bioscientifica Ltd
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227 :3 R57transcription factors, has also been implicated, eg GATA2
during TR-mediated repression of TSHB (Matsushita et al.
2007, Santos et al. 2011).
Additional modulators of TSH secretion include hypo-
thalamic dopamine and somatostatin (inhibitory), and the
influence of feeding behaviour, glucocorticoids, severe
illness, cold, and circadian rhythm (Fliers et al. 2006).Genetic causes of central congenital
hypothyroidism
Isolated central hypothyroidism is a rare entity, with an
estimated incidence of 1:65 000 and known genetic causes
affect the TSH biosynthetic pathway, comprising
mutations in TSHB and TRHR, and IGSF1 (Joustra et al.
2013a). In the majority of patients, CCH occurs in the
context of combined pituitary hormone deficiencies, and
additional syndromic features may manifest depending on
its genetic aetiology. Only a minority of individuals will
harbour mutations in known transcription factors such as
POU1F1, PROP1, HESX1, LHX3, LHX4, SOX3 and OTX2
that are implicated in pituitary development (Alatzoglou
& Dattani 2009, Kelberman et al. 2009). This suggests that
other, as yet unidentified genetic or epigenetic factors,
may be implicated in the aetiology of CCH.Isolated central congenital hypothyroidism
TSHB mutations
Biallelic loss of function, TSHB mutations are associated
with severe central hypothyroidism of neonatal onset for
which additional biochemical hallmarks include elevated
pituitary glycoprotein a subunit, and an impaired TSH
response to TRH administration, despite a preserved rise in
serum Prolactin (Bonomi et al. 2001) (Table 1). Con-
comitant neurodevelopmental impairment is a frequent
finding, and usually correlates with treatment delay due to
the fact that individuals evade detection on TSH-based,
primary CH screening programmes, and remain undiag-
nosed until their profound congenital hypothyroidism
manifests clinically. In cases who are diagnosed and
treated from birth due to ascertainment following a prior
genetic diagnosis in their family, developmental outcome
is often improved (Brumm et al. 2002, Karges et al. 2004).
Heterodimeric TSH comprises the common a subunit
(aGSU) shared with other glycoprotein hormone (LH, FSH,
CG) family members and a hormone-specific b-subunit
(TSHB) in which naturally-occurring mutations either
truncate the protein, or perturb key structural featureshttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0341
 2015 The authors
Printed in Great Britainrequired for heterodimeric integrity (Fig. 4). In common
with other cysteine-knot proteins, a central cysteine knot
in each subunit is surrounded by two b-hairpin loops on
one side, and a long loop on the other. A ‘seat belt’ formed
from the TSH b subunit, wraps around the long loop of the
a-subunit and forms an intra-molecular disulfide ‘buckle’
to stabilize the heterodimer and additional a-b subunit
interactions occur around a conserved CAGYC sequence
motif (Szkudlinski et al. 2002, Jiang et al. 2014). Conserved
cysteine residues in all glycoprotein hormone b-subunits
form disulphide bridges central to the three-dimensional
structure of the protein, and alignment with b-hCG, for
which the crystal structure has been solved, predicts
similar interactions in TSHB. Disulphide bridges between
Cys22-Cys72, Cys47-Cys103, and Cys51-Cys105 are
thought to maintain the cystine-knot motif; Cys39-
Cys125 and Cys108-Cys115 are thought to be integral to
‘seatbelt’ formation; and an interaction between Cys37-
Cys87 is thought to link the two b-hairpin loops
(Szkudlinski et al. 2002, Jiang et al. 2014).
Nine, naturally-occurring, TSHB mutations have been
described, including missense (C108Y, C105R, G49R),
nonsense and frameshift mutations (p.E32*, p.Q69*,
p.C125Vfs*10, p.F77Sfs*6) (Hayashizaki et al. 1989,
Dacou-Voutetakis et al. 1990, Medeiros-Neto et al. 1996,
Bonomi et al. 2001, Vuissoz et al. 2001, Sertedaki et al.
2002, Morales et al. 2004, Baquedano et al. 2010), as well as
two splice-site mutations (c162GOA, c.162C5 GOA)
(Pohlenz et al. 2002, Baquedano et al. 2010). More
recently, a homozygous TSHB deletion was reported
(Hermanns et al. 2014). All the missense mutations disrupt
key disulphide bridges required for heterodimeric integrity
or disrupt the CAGYC region (Fig. 4). (For the purposes of
this review, the nomenclature of these mutations follows
the most recent HGNC guidelines to include the 20 amino
acid signal peptide of TSHB, such that the annotation may
differ from that cited in the original published articles.)
The most frequently described mutation is a single
nucleotide deletion (c373delT) leading to a cysteine 125 to
valine change (p.C125V) and subsequent frameshift and
premature stop codon at position 134 (p.C125Vfs*10)
(Medeiros-Neto et al. 1996). This has been reported
worldwide in several, non-consanguineous families,
although a founder effect was also described in three
German kindreds (McDermott et al. 2002, Brumm et al.
2002, Deladoey et al. 2003, Domene et al. 2004, Karges
et al. 2004). Functional studies have demonstrated that
replacement of the cysteine at position 125 with valine,
rather than subsequent deletion of the terminal 13 amino
acids, impairs the bioactivity of the mutant TSH, byPublished by Bioscientifica Ltd
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TSHβ
TSHα
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Figure 4
Model for heterodimeric thyroid stimulating hormone (TSH) bound to the
TSH receptor (TSHR) illustrating the position of naturally occurring TSHB
loss-of-function mutations associated with congenital central hypothyr-
oidism. The model was generated using PHYRE for predicting TSHbeta
subunit (TSHb) structure and was modelled onto FSH-FSHR (1!wd) and the
TSHR-K1-70FAB (2!wt) structure using PYMOL. Colour coding is as follows:
Green TSHR, Red: TSH alpha subunit (TSHa, aGSU), Blue: TSHb. Specific
structural features required to maintain the heterodimeric structure: Cyan
‘seatbelt’ region, Yellow: cysteines conserved throughout cysteine knot
proteins and involved in disulphide bridge formation. Spheres denote
TSHB mutations: C105R; C108Y; C125Vfs*10 (yellow) disrupt disulphide
bridges, G49R (purple) is located in the conserved CAGYC region and E32*;
Q69*; F77Sfs*6 (orange) truncate the protein prematurely. The nomen-
clature of these mutations follows the most recent HGNC guidelines to
include the 20 amino acid signal peptide of TSHB, thus may differ from that
cited in the original articles. Nomenclature can be converted to that
previously published for missense mutations by subtracting 20 eg Q69*
new nomenclatureZQ49X old nomenclature.
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hypothyroidism
227 :3 R59disrupting the Cys125-Cys39 disulphide bond which
forms the ‘buckle’ of the TSHB ‘seatbelt’ surrounding the
alpha subunit (Medeiros-Neto et al. 1996).
Mutations (p.G49R, p.Q32*), which disrupt hetero-
dimer formation between TSHa and b polypeptides
generally result in unmeasurable serum TSH concen-
trations, whereas mutations (eg p.Q69*, IVS2C5 GOA,
c.373delT), which preserve formation of some mutant,
heterodimeric TSH expressing the epitopes recognized by
the anti-TSH monoclonal antibody, enables TSH to be
detected in an immunoassay-dependent manner. Thus,http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0341
 2015 The authors
Printed in Great Britainsome cases may have detectable levels of immunoreactive
TSH, but these species will lack normal bioactivity
(Bonomi et al. 2001). In contrast, a recent report describes
a TSHB variant with impaired immunoreactivity but
normal bioactivity (c.223AOG, p.R75G including the
signal peptide). Two clinically euthyroid siblings, both
homozygous for the variant, exhibited normal thyroid
hormone levels but undetectable TSH specifically in
Siemens assay platforms, due to poor TSH adsorption by
the monoclonal antibody (Pappa et al. 2015). Although
affected individuals are euthyroid, this variant had
previously been detected in South East Asian patients,
some of whom had consequently been inappropriately
treated with antithyroid drugs (Drees et al. 2014).
Alternatively, the undetectable TSH may erroneously
suggest central hypothyroidism on CH screening.TRHR mutations
Biallelic TRHR mutations are the least common cause of
isolated congenital hypothyroidism, and have hitherto
been described in only three cases from two unrelated
kindreds. In both families, the male Probands exhibited
subnormal T4 concentrations 40% to 88% lower limit of
the normal range, with associated clinical manifestations
predominantly comprising growth retardation and a
delayed bone age. There was reportedly no attributable
neurological deficit despite presentation of patients at age
9 and 11 years, suggesting preservation of sufficient
thyroid hormone production in infancy to prevent overt
mental retardation. Pituitary TSH synthesis was
inadequate (in conjunction with low T4, serum TSH was
inappropriately normal), but circulating T4 levels rose
appropriately following levothyroxine withdrawal, indi-
cating that synthesis of bioactive TSH could occur in the
absence of TRH signalling (Collu et al. 1997, Bonomi et al.
2009). Rhythmic TSH secretion was also preserved and
pituitary morphology was normal (Collu et al. 1997,
Bonomi et al. 2009).
Intriguingly, a female with a homozygous, nonsense
TRHR mutation (p.R17*), was only diagnosed with central
hypothyroidism following family screening at the age of
33, having previously achieved two normal pregnancies
with subsequent lactation. Although TRHR is expressed in
lactotrophs as well as thyrotrophs, and stimulates
prolactin secretion in response to i.v. TRH administration,
its physiological role in these cells is unclear. Both male
and female individuals with biallelic TRHR mutations had
absent TSH and prolactin responses to TRH adminis-
tration. However, the obstetric history in the p.R17*Published by Bioscientifica Ltd
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227 :3 R60homozygous female suggests that TRH action is not
obligatory for pregnancy and lactation in humans
(Bonomi et al. 2009).
In common with all family A G-protein-coupled
receptors (GPCR’s), the structure of TRHR includes an
extracellular N-terminus and intracellular C-terminus,
flanking seven transmembrane domains connected by
three intracellular and three extracellular loops, which
form a ligand-binding pocket within the plasma mem-
brane. TRH-binding results in a conformational change
involving transmembrane helices 5 and 6 and the third
intracellular loop, with subsequent carboxyterminal
domain-mediated G-protein coupling (Hinkle et al. 2012)
(Fig. 5). In both families with TRHR defects, the mutations
have been highly deleterious, resulting in complete
abrogation of TRHR function. The first case was
compound heterozygous for a maternally-inherited non-
sense mutation (p.R17*) truncating the protein before
the transmembrane domains, and a paternally-inherited
in-frame deletion of three amino acids (S115, I116, and
T117) with one substitution (p.A118T) in the thirdR17
N-terminus
C-terminus
S115
Extracellular
space
Intracellular
space
Cell
membrane
Figure 5
Crystallographic modeling of TRHR showing the positions (red spheres)
of the two previously described mutations associated with central
hypothyroidism: R17X truncating the protein in the extracaellular
domain and an in-frame deletion of 3 amino acids (Ser115-Thr117) plus a
missense change (Ala118 for Thr118; p.S115-T117delCT118) located at the
cytoplasmic end of the third transmembrane domain of the receptor
The TRHR structural model was generated by homology modeling using
the PHYRE server and Pymol. The N-terminal start codon and C-terminal
end codon are highlighted in green.
http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0341
 2015 The authors
Printed in Great Britaintransmembrane domain. In the second reported kindred,
affected individuals were homozygous for the p.R17*
mutation (Collu et al. 1997, Bonomi et al. 2009) (Fig. 4).
Endocrine abnormalities in TRHR null humans are
recapitulated in mice lacking Trhr1 who also exhibit
subnormal T4 and T3 levels with inappropriately normal
TSH (Table 1). Normal somatotrope, thyrotrope, and
lactotrope numbers confirm that TRHR is not needed for
the development or maintenance of TRH target cells, with
preservation of fertility, pregnancy and lactation in
females although both basal serum prolactin and lacta-
tion-stimulated prolactin mRNA are decreased. Increased
fasting glucose concentrations were also observed in the
mice. However, there is currently no evidence for an
extrapituitary phenotype in humans with TRHR
mutations (Rabeler et al. 2004, Zeng et al. 2007).IGSF1 mutations
Mutations in the immunoglobulin superfamily member 1
(IGSF1) gene are the most recently identified cause of
central hypothyroidism, with an estimated incidence of
up to 1:100 000 (Sun et al. 2012, Joustra et al. 2013a). The X
chromosome located IGSF1 gene encodes a membrane
glycoprotein which was first thought to be an inhibin
co-receptor in the pituitary, but recent binding and in vivo
data from mice and humans suggests that this is unlikely
(Chong et al. 2000, Chapman & Woodruff 2001, Chapman
et al. 2002, Bernard et al. 2003). At mRNA level, IGSF1 and
its murine homolog Igsf1 are abundantly expressed in
Rathke’s pouch (the developing pituitary primordium)
and in adult pituitary gland (Sun et al. 2012). A paucity
of reliable antibodies has hampered expression studies of
the human protein; however, in murine pituitary, IGSF1
protein is detected in thyrotropes, somatotropes and
lactotropes, but not gonadotropes, and in the rat, pituitary
expression is also confined to cells of the Pou1f1 lineage
(Sun et al. 2012, Joustra et al. 2015a). Although a role for
IGSF1 in pituitary and hypothalamic physiology is
supported both by its cellular expression pattern and by
endocrine consequences of IGSF1 deficiency in mice and
humans, its precise physiological function in both species
remains undefined (Sun et al. 2012).
The IGSF1 protein undergoes co-translational proteo-
lysis such that the carboxyterminal portion trafficks to
the plasma membrane where it is expressed as a large
extracellular domain with a short intracellular cyto-
plasmic tail (Robakis et al. 2008). Fourteen pathogenic
mutations in the IGSF1 gene have been described, in cases
from the Netherlands, the UK, Italy and Japan (Sun et al.Published by Bioscientifica Ltd
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227 :3 R612012, Nakamura et al. 2013, Tajima et al. 2013), all of
which impair either protein maturation or membrane
trafficking, resulting in decreased plasma membrane
expression of IGSF1. The twelve missense or truncating
mutations are all located in the extracellular portion of the
carboxyterminal domain; the remaining two mutations
are whole gene deletions (Fig. 6).
Four publications have documented the consequences
of loss of function mutations in IGSF1 in humans (Sun
et al. 2012, Joustra et al. 2013b, Nakamura et al. 2013,
Tajima et al. 2013). All affected males exhibited central
hypothyroidism, either isolated, or associated with hypo-
prolactinaemia (subnormal basal prolactin levels) (67%
cases). A minority of patients required treatment for
transient, partial, growth hormone deficiency in child-
hood; paradoxically, in some European cases, circulating
IGF1 levels tended to increase with age relative to the age-
matched reference interval and several patients developed
acromegaloid features in late adulthood. Pubertal develop-
ment was usually disharmonious, with a delayed pubertal
growth spurt and testosterone rise despite normal onset
of testicular growth. All evaluable European males sub-
sequently developed adult macroorchidism, with ultra-
sonographic testicular volumes close to 50 ml in two cases
(Sun et al. 2012, Joustra et al. 2013b). Additionally,
phenotyping of female IGSF1 mutation carriers indicated
that although IGSF1 deficiency is X-linked, one-third of
heterozygous females exhibit central hypothyroidism, andE750Kfs*2
A713_K721del
Q645*
NH2
S
Hydrophobic
linker
Internal signal sequence
126- and 32
Figure 6
Schematic illustrating the protein domain structure of IGSF1 with the
internal signal peptide directing cleavage of the carboxy-terminal domain
denoted by a dashed line. Positions of naturally-occurring mutations
associated with congenital central hypothyroidism are denoted; all are
http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0341
 2015 The authors
Printed in Great Britainup to 11% demonstrate hypoprolactinaemia. Intriguingly,
four of 18 females investigated had undergone surgical
resection of benign ovarian cysts, suggesting possible
shared pathogenetic mechanisms with the macroorchid-
ism observed in males (Table 1). Skewed X inactivation
was not a reliable predictor of endocrinopathy in female
cases (Joustra et al. 2013b).
Murine studies have suggested that impaired TRH
signaling may play a role in the central hypothyroidism
associated with IGSF1 deficiency. Male igsf1 deficient mice
are centrally hypothyroid, with decreased TRHR mRNA
expression in the pituitary. In keeping with impaired TRH
signaling, serum T3 and TSH levels are subnormal despite
normal pituitary TSHB mRNA synthesis; and there is
a blunted TSH response to TRH administration. Hypo-
thalamic TRH mRNA levels are elevated, suggesting intact
synthesis of TRH (Bernard et al. 2003, Sun et al. 2012)
(Table 1). Most humans with hemizygous IGSF1
mutations exhibit biochemical hypothyroidism that is
comparable to biallelic TRHR mutation cases, comprising
mild-moderate CCH with detectable TSH and apparently
normal neurological development even when the diag-
nosis is delayed until adulthood. These features would be
consistent with impaired TRH signaling being the basis of
the central hypothyroidism phenotype in the human
IGSF1 deficiency, with such defective signaling also
predicted to result in decreased bioactivity of TSH. Such
qualitative assessment of TSH, either directly or indirectly8
S863F
770N C947R
W977* R1189*
E1200Rfs*3W1173*
COOH
8-kb deletions
IGSF1-carboxyterminal domain
Extracellular domain Transmembrane
domain
Cytoplasmic
domain
V1082E
P1082Wfs*39
located within the carboxyterminal domain. Two whole gene deletions
(below) have also been reported (Sun et al. 2012, Nakamura et al. 2013,
Tajima et al. 2013).
Published by Bioscientifica Ltd
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227 :3 R62by measurement of rise in circulating T3 and T4 increment
during a prolonged TRH stimulation test, would therefore
be informative in this context (Yamada & Mori 2008).
The mechanisms underlying the macroorchidism and
disharmonious pubertal development seen in IGSF1
deficient males remain to be ascertained, and mechanistic
possibilities remain speculative. Excess hypothalamic
TRH, acting on gonadotropes which express TRHR but
not IGSF1, could drive macroorchidism via an FSH-
mediated process, consistent with observations that
serum FSH was always higher than serum LH, in IGSF1-
deficient males (Kugler & Huseman 1983, Ryan et al. 2007,
Sun et al. 2012). Alternative contributory factors could
include hypothyroxinaemia acting directly to increase
Sertoli cell number and potentially also underlying the
delayed testosterone rise (Weber et al. 2003, Holsberger &
Cooke 2005, Joustra et al. 2013a), although the absence of
macroorchidism in other forms of congenital central
hypothyroidism argues against this as the sole cause. A
further possibility would be a direct testicular effect of
IGSF1, but it remains unclear whether IGSF1 protein is
expressed in human testis. Rats exhibit testicular
expression of IGSF1 in adult Sertoli cells during stages
XIII through VI of the seminiferous epithelium, and in
elongating spermatids during epithelial stages X through
XIII (Joustra et al. 2015a). IGSF1 deficient mice exhibit
greater testicular weight but this is proportional to their
increased body mass, and they do not express IGSF1
protein in testis (Sun et al. 2012).
Hitherto, studies of the endocrine effects of IGSF1
deficiency may been confounded by selection bias, with
gene screening being undertaken predominantly in cases
of central hypothyroidism. More recently, IGSF1 has been
sequenced in euthyroid patients with X-linked consti-
tutional delay of growth and puberty, and individuals
with gigantism or acromegaly, with no evidence for a
primary causative role for genetic variation in IGSF1 in
these disorders (Faucz et al. 2015, Joustra et al. 2015b).
IGSF1 remains a highly polymorphic gene with an as
yet incompletely characterized role both in anterior
pituitary cells of the POU1F1 lineage, and in pubertal
and gonadal development. Additionally, significant phe-
notypic variability amongst individuals harbouring IGSF1
mutations, suggests that its role may be influenced by as
yet unidentified genetic or environmental modifiers.Combined pituitary hormone deficiencies
Central congenital hypothyroidism in association with
combined pituitary hormone deficiencies may behttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0341
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Printed in Great Britaini) syndromic, resulting from mutations in early transcrip-
tion factors, and associated with developmental abnorm-
alities (eg septo-optic dysplasia and its variants,
holoprosencephaly and midline defects, ocular or skeletal
defects, and intellectual impairment) or ii) non syndromic
resulting from mutations in late transcription factors
(PROP1, POU1F1). The variable phenotypes, associations
and MRI findings are summarized in Table 1.
Septo-optic dysplasia (SOD) is defined by the com-
bination of two of the following i) optic nerve hypoplasia
(ONH) ii) midline forebrain defects (ie agenesis of
the corpus callosum, absent septum pellucidum) and
iii) pituitary hypoplasia with variable hypopituitarism.
The commonest endocrine defect is GH deficiency
followed by TSH and ACTH deficiency, whilst gonado-
tropin secretion may be retained. Mutations in HESX1,
OTX2, and SOX3 have been identified in patients with TSH
deficiency and SOD (Dattani et al. 1999, Woods et al. 2005,
McNay et al. 2007). There is increasing evidence of overlap
in the aetiology of conditions that were previously
considered to be discrete, such as Kallmann syndrome,
SOD and combined pituitary hormone deficiencies as
mutations in the same array of genes (KAL-1, PROKR2,
FGF8, FGFR1) have now been implicated in their aetiol-
ogy. In this respect, the TSH deficiency may be part of the
initial presentation or evolving phenotype of these
patients (McCabe et al. 2011, McCabe et al. 2013).
Mutations in the Lim homeodomain transcription
factors (LHX3, LHX4) lead to multiple pituitary hormone
deficiencies, including TSH deficiency. Expression of Lhx3
is initially detected uniformly within Rathke’s pouch from
E9.5 and by E16.5 it is expressed in the developing anterior
and intermediate pituitary where its expression persists
into adulthood. Mice with a targeted homozygous
disruption of Lhx3 die shortly after birth and exhibit
pituitary aplasia. Although Rathke’s pouch is initially
formed, its expansion is arrested by E12.5 and lacks almost
all of the hormone-secreting cell types, containing only
a small population of corticotropes (Mullen et al. 2007,
Kelberman et al. 2009). Patients with homozygous or
compound heterozygous LHX3 mutations have an evol-
ving endocrine phenotype involving GH, PRL, LH, FSH
and TSH deficiency (Mullen et al. 2007). Although ACTH
seems to be spared in the majority of patients, ACTH
deficiency has also been described (Rajab et al. 2008). The
anterior pituitary morphology is variable (hypoplastic,
enlarged or presence of microadenoma) with a eutopic
posterior pituitary. Patients may have cervical abnormal-
ities, with or without restricted neck rotation,Published by Bioscientifica Ltd
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et al. 2007).
Lhx4 is closely related to Lhx3; it is initially expressed
throughout the Rathke’s pouch at E9.5. However, in
contrast to Lhx3, its expression is transient, restricted to
the future anterior lobe and down-regulated by E12.5.
Homozygous Lhx4 null mice die shortly after birth from
lung defects; the anterior lobe of Lhx4K/K mice contains
all of differentiated cell types but there is reduction in cell
proliferation (Mullen et al. 2007, Kelberman et al. 2009).
Patients with heterozygous missense or frameshift LHX4
mutations have GH and variable gonadotrophin, TSH and
ACTH deficiencies, a hypoplastic anterior pituitary with/
without an undescended/ectopic posterior pituitary and
other abnormalities including a poorly formed sella
turcica, pointed cerebellar tonsils or Chiari malformation
(Castinetti et al. 2008, Pfaeffle et al. 2008)
Mutations in the transcriptional repressor HESX1 are
associated with SOD, CPHD and IGHD (Dattani et al. 1998,
Carvalho et al. 2003, McNay et al. 2007, Kelberman et al.
2009). Endocrine deficits may include GH, TSH, ACTH and
gonadotrophin deficiencies. The anterior pituitary may be
hypoplastic or absent whereas the posterior pituitary is
usually ectopic but occasionally may be eutopic. In mice,
Hesx1 is expressed in the anterior neural ectoderm, and
thereafter in the forebrain and developing pituitary,
although its expression is switched off in the forebrain at
E9, and in Rathke’s pouch after E13.5. Homozygous null
mutant mice have severe eye, forebrain and pituitary
defects (Dattani et al. 1998, Sajedi et al. 2008), a phenotype
that is reminiscent of SOD.
OTX2 (Orthodentic homeobox 2) is a transcription
factor required for the formation of anterior structures and
maintenance of the forebrain and has been implicated
in 2–3% of anophthalmia/microphthalmia syndromes in
humans (Boncinelli & Morgan 2001, Kurokawa et al.
2004). In mice, the expression of Otx2 is localised to
developing brain, eye, nose and ear. Homozygous knock-
out mice die at midgestation with severe brain abnorm-
alities, whereas heterozygous mutants have a variable
phenotype ranging from normal to severe eye and brain
abnormalities (anophthalmia, holoprosencephaly or
anencephaly) (Acampora et al. 1995). Heterozygous
mutations in OTX2 have highly variable pituitary pheno-
types that range from partial IGHD to hypopituitarism,
with or without an ectopic posterior pituitary and, rarely,
even without an ocular phenotype (Dateki et al. 2008,
Diaczok et al. 2008, Tajima et al. 2009).
Over- and under-dosage of SOX3 has been
implicated in the aetiology of X-linked hypopituitarismhttp://joe.endocrinology-journals.org
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growth hormone deficiency to combined pituitary
hormone deficiency, including evolving TSH deficiency,
with or without variable mental retardation or learning
difficulties. (Laumonnier et al. 2002, Woods et al. 2005,
Alatzoglou & Dattani 2009). MRI findings include an
undescended posterior pituitary, anterior pituitary hypo-
plasia, or persistence of the craniopharyngeal canal
(Woods et al. 2005, Alatzoglou et al. 2014).
PROP1 mutations are the most common cause of
CPHD, including GH, TSH, gonadotropin, and evolving
ACTH deficiencies of variable onset. Recessive PROP1
mutations are associated with GH, TSH, prolactin and
gonadotropin deficiency, although the timing and extent
of these deficits vary and the full phenotype may not be
evident from the outset. For instance, patients
homozygous for the p.R120C mutation may first present
in childhood with GHD before the later development of
TSH, prolactin and gonadotropin deficiencies (Fluck et al.
1998). Most patients with PROP1 mutations have a
hypoplastic or normal anterior pituitary gland with a
eutopic posterior pituitary. However, there have been
reports of an enlarged anterior pituitary at initial scanning
in childhood with spontaneous involution over time,
often waxing and waning before eventual involution
(Voutetakis et al. 2004, Turton et al. 2005).
Patients with autosomal recessive and dominant
POU1F1 mutations have GH and PRL deficiencies, that
are generally present from early life, and are associated
with a normal or hypoplastic anterior pituitary, whilst TSH
deficiency can be highly variable. Although the majority
have early TSH deficiency, hypothyroidism may also occur
later in childhood. A patient with a POU1F1 mutation
identical to that found in an unrelated patient who
developed central hypothyroidism in the second year of
life, has been reported with GH and PRL deficiency and yet
normal thyroid function at the age of 21 years. (Turton
et al. 2005).Diagnosis of central congenital hypothroidism
The TSH-based protocol used by most neonatal CH
screening programmes will unfortunately only detect
primary CH since CCH is usually associated with
inappropriately normal or low TSH. However, the merits
of screening for CCH remain a subject of debate with
arguments against screening citing its relative rarity and
the presumption that it is usually mild and not likely to be
associated with brain damage (Price & Weetman 2001,
La Franchi 2010, La Franchi 2011). In the Netherlands,Published by Bioscientifica Ltd
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measurement of TSH, T4 and thyroxine binding globulin
(TBG) results in a diagnosis of CCH in as many as 1 in
16 000 newborns, the majority of whom will have
additional pituitary hormone deficits (van Tijn et al.
2005, Kempers et al. 2006). Advantages to case detection
by screening include prevention of life-threatening
hypoglycaemia due to coexisting GH and/or ACTH
deficiency in these individuals as well as enabling early
neonatal levothyroxine replacement. A recent study
demonstrated that more than 50% of children with CCH
will have moderate or severe hypothyroidism, such that
the potential neurological sequelae of delayed diagnosis
should not be underestimated (Persani 2012, Zwaveling-
Soonawala et al. 2015). However, although the recent ESPE
CH guidelines acknowledge that screening for CCH fulfils
generally accepted disease screening criteria, studies
confirming superiority of detection through screening
compared with case identification by clinical ascertain-
ment are lacking (Fisher 2005, Leger et al. 2014).
A high index of suspicion is required when investi-
gating for CCH, since early clinical diagnosis is often
difficult, and unless the hormone deficit is profound,
classical signs of hypothyroidism may be absent. The
mainstay of biochemical diagnosis remains the association
of low free T4 concentrations with inappropriately low or
normal TSH concentrations in the absence of immuno-
assay interference (Ferretti et al. 1999, Beck-Peccoz 2011,
Persani 2012). Circulating T3 levels are often normal,
due to increased DIO2 activity (Alexopoulou et al. 2004,
Sun et al. 2012).
Although biochemical diagnosis of overt central
hypothyroidism is generally unequivocal, detection may
be more challenging in mild cases where fT4 is only
marginally subnormal or when hypothalamic dysfunction
results in elevated immunoreative TSH with subnormal
bioactivity (Beck-Peccoz 2011). In situations where central
thyroid dysfunction evolves with time (eg in children with
POU1F1 mutations), declining fT4 concentrations may be
an early indicator of CCH, with a time-related decline in
fT4 of O20% quoted diagnostically in individuals with
acquired pituitary disease (Alexopouou et al. 2004).
Biochemical markers of thyroid hormone action (eg
CPK, cholesterol), lack diagnostic sensitivity but may
have a role in monitoring treated cases and may support
a diagnosis of CCH (Ferretti et al. 1999). A recent study
suggests that T3-dependent echocardiographic parameters
may be useful in identifying adults with subclinical central
hypothyroidism (Doin et al. 2012). Additional tests that
may have a diagnostic role in mild CCH includehttp://joe.endocrinology-journals.org
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absent or blunted even in subclinical cases (Rose et al.
1990, Rose 1995, Roelfsema & Veldhuis 2013). The TSH
index, in which a log-linear relationship between fT4 and
TSH is used to predict the normal amount of feedback-
induced change in log TSH per change in fT4, has also been
proposed as an estimate of pituitary thyrotroph function,
although extrapolation of these results to the paediatric
population is challenging (Jostel et al. 2009).
The role of TRH testing in CCH remains controversial,
both at diagnosis and in discriminating between pituitary
and hypothalamic pathology. Initial studies found a
blunted TSH rise to be indicative of pituitary hypothyr-
oidism, whereas an exaggerated, delayed or prolonged
TSH response was associated with tertiary hypothyroidism
(Costom et al. 1971, Faglia et al. 1973). However, more
recent studies in children with central hypothyroidism
suggest that TRH testing has both a poor negative
predictive value, and an inability to distinguish between
hypothalamic and pituitary defects (Mehta et al. 2003). In
a study of 54 children with central hypothyroidism, 23.3%
had a normal TRH test, only 30% had an absent or blunted
TSH response suggestive of pituitary disease, whilst 30%
had a delayed hypothalamic response and 16.7% a brisk
response (Mehta et al. 2003). In a different setting, a
prospective study of twenty infants diagnosed with central
hypothyroidism on neonatal screening, concluded that
TRH testing is useful for diagnosis and for distinguishing
between patients likely to have isolated or combined
pituitary deficiencies, provided that the TSH response to
TRH is assayed for at least 180 min post hormone
administration. In this study, the majority of patients
with type 2 responses had isolated TSH deficiency (67%),
whilst all patients with type 3 TSH responses to TRH had
combined pituitary deficiencies (van Tijn et al. 2008). A
prolonged TRH test with a normal TSH increment may
enable indirect assessment of TSH bioactivity, quantified
by the rise in fT3 and fT4 levels at 120 min after TRH
injection (Yamada & Mori 2008). However, although this
information may help define the mechanism of CCH,
further studies are needed to determine normal thyroid
hormone responses at these timepoints. In isolated TSH
deficiency, additional hormone measurements during
TRH testing may enable differentiation between a likely
TSHB mutation (preserved prolactin and a-subunit
responses) and TRHR mutation (blunted responses)
(Collu et al. 1997, Bonomi et al. 2001).
In the presence of central hypothyroidism, detailed
investigation of the hypothalamo–pituitary axis is indi-
cated as the majority of patients (up to 78% to 89%) willPublished by Bioscientifica Ltd
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et al. 2003, Van Tijn et al. 2005). In a series of children with
central hypothyroidism, GH deficiency was the most
common associated hormone deficiency (89%), followed
by ACTH (78%) and gonadotropin deficiency (46%),
whilst posterior pituitary dysfunction was evident in a
small percentage of patients (13%), all of who had SOD
(Mehta et al. 2003). In this respect, MR imaging is
important to detect structural pituitary abnormalities
and midline or other CNS defects, and its results may
guide genetic testing. Although patients with congenital
central hypothyroidism may have a high prevalence of
neonatal complications (hypoglycaemia, persisting jaun-
dice, sepsis, seizures, feeding difficulties), the diagnosis of
central hypothyroidism was only made in 28% during the
neonatal period (Mehta et al. 2003).
In specific cases, there is a role for targeted genetic
screening, depending on the phenotype (Fig. 7). Patients
with mutations in transcription factors (eg PROP1, HESX1,
SOX3) require long-term surveillance for evolving ACTH
and other pituitary hormone deficiencies. Conversely,
identification of a genetic defect specific to the TSH
biosynthetic pathway (TSHB, TRHR) enables reassuranceClinical phenotype
Isolated TSH
deficiency
X
Mac
SOD and variants
Radiologi
ph
MPHD or isolated
deficiencies
Phenotype
Ocular phenotypes
Complex
phenotypes
No synd
MRI: O
midline
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MRI: A
Ano/mi
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Figure 7
Proposed strategy for genetic testing in cases with CCH. MPHD, multiple
pituitary hormone deficiencies; ONH, optic nerve hypoplasia; HPE,
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of families with TRHR or IGSF1 mutations also highlight
the fact that family screening following diagnosis in a
young proband, may identify apparently healthy first,
second or third-generation family members with hitherto
undiagnosed central hypothyroidism. Untreated subclini-
cal hypothyroidism is associated with adverse cardiometa-
bolic risk, thus these individuals, who have overt central
hypothyroidism may benefit from levothyroxine treat-
ment both for cardiovascular health and for quality of life
(Razvi et al. 2007, Singh et al. 2008, Bonomi et al. 2009).Treatment of central hypothyroidism
Data regarding treatment of central hypothyroidism
primarily comes from adults with acquired hypo-
thalamic–pituitary defects and definition of treatment
targets remains challenging, since TSH cannot be used as
a biomarker of euthyroidism. Furthermore, the negative
feedback mechanism in central hypothyroidism may
exhibit altered sensitivity to thyroid hormone, such that
TSH concentrations above 1.0mU/l may reflect insufficient
levothyroxine replacement (Carrozza et al. 1999, Ferretti-linked,
roorchidism
cal/extrapituitary
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replacement is best assessed by fT4 measurement with
the general consensus being that fT4 levels should be
maintained in the mid-upper half of the normal range,
although a lower target fT4 may be appropriate in the
elderly (Ferretti et al. 1999, Slawik et al. 2007, Iverson &
Mariash 2008, Koulouri et al. 2011). fT3 may be more
sensitive in detecting overtreatment. Assessment of
alternative biomarkers has identified that soluble inter-
leukin 2 receptor (sIL2R) has some utility, but detects
overtreatment more readily than undertreatment. SHBG,
bone turnover markers, and cholesterol are all sensitive to
changes in fT4, but the fact that they are also influenced
by GH and gonadal status, renders them unreliable in
combined pituitary hormone deficits (Ferretti et al. 1999).
It is imperative that cortisol deficiency is detected and
treated before thyroid hormone replacement to avoid a
hypoadrenal crisis. Once this is achieved, the drug of
choice for treating central hypothyroidism is levothyrox-
ine, with no current evidence to support T3/T4 com-
bination therapy (Slawik et al. 2007). The dose needs to be
tailored to the age and body weight of the patient, and
must accommodate the influence of other hormone
deficiencies or drugs. A reasonable target daily replace-
ment dose of L-T4 would initially be 1.1 mcg/kg in patients
over 60 years of age, 1.3 to 1.6 mcg/kg for younger adults
and 50 to 100 mg/m2 per day in children (Ferretti et al.
1999, Slawik et al. 2007, Lania et al. 2008, Koulouri et al.
2011). In children, full replacement should be started
immediately and monitored every 2 to 4 weeks initially
whereas more cautious dosing may be necessary in the
elderly or those with cardiac morbidities. Dose require-
ments may increase with concomitant oestrogen replace-
ment which increases thyroid hormone binding proteins,
and GH replacement, which can also unmask central
hypothyroidism (Arafah 2001, Porretti et al. 2002).Future directions
The molecular basis for CCH remains to be ascertained in
the majority of cases, raising aetiological questions in this
subset. Candidate genes identified from murine models
have been helpful in elucidating the basis of combined
pituitary hormone deficiencies, and there are additional
null mouse models of central hypothyroidism, which
implicate other genes as potential candidates for human
CCH. Such models include Trh K/K mice which exhibit
central hypothyroidism with elevated TSH and hyper-
glycaemia and glycoprotein a subunit (Cga/Gsu) K/K
null mice in whom TSH, T4, FSH and LH are undetectablehttp://joe.endocrinology-journals.org
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despite the critical role of GATA2 and PITX1 in the
development of thyrotropes in murine models, no
mutations have as yet been reported in patients with
CCH. Perturbed thyroid hormone action and disruption of
normal thyroid hormone-mediated negative feedback in
the hypothalamus and pituitary may also cause CCH thus
mice expressing a mutant NCOR1 corepressor exhibit
central hypothyroidism due to a reset hypothalamic–
pituitary thyroid axis (Astapova et al. 2011). In affected
humans, studies using exome sequencing may also help
elucidate less readily predictable causes.
Amongst the known genetic causes of CCH, the
function of IGSF1 remains poorly understood and further
in vitro and in vivo studies are required to delineate its
mechanistic role in the anterior pituitary and its effects on
testicular growth. Although current data suggest it is
required for adequate TRHR mRNA expression, the
expression of IGSF1 in all cells of the POU1F1 lineage
and observed abnormalities of other hormone levels (GH,
PRL, Testosterone) in deficient humans suggest that its
role is more complex. Other cell surface immunoglobulin
superfamily members bind specific antigens and interact
with other receptors, such that a role for IGSF1 in
paracrine signaling in the pituitary is plausible (Joustra
et al. 2013a,b, Tajima et al. 2013). Prospective follow up of
patients with IGSF1 mutations will help define the natural
history of the disease, addressing questions such as
whether central hypothyroidism can evolve in carrier
females. Additionally, genetic and environmental modi-
fiers of the IGSF1-deficiency phenotype within individual
kindreds have yet to be determined.
Long-term outcome studies in congenital central
hypothyroidism are required, in particular to formally
assess neuropsychological outcomes as a means of
assessing adequacy of current diagnostic and treatment
algorithms. Identification of robust biochemical or phys-
iological biomarkers of thyroid hormone action will also
help in diagnosis or treatment monitoring.Take home messages
† CCH has a higher incidence than previously thought
(1:16 000), and delayed diagnosis may result in
neurodevelopmental delay.
† CCH will evade diagnosis on TSH-based screening
programmes, therefore a high index of suspicion is
needed for prompt detection. The mainstay of bio-
chemical diagnosis is the presence of subnormal T4Published by Bioscientifica Ltd
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of assay interference.
† CCH may be isolated or occur as a component of
combined pituitary hormone deficiencies (majority of
cases). Genetic ascertainment may predict evolution
of other hormone deficits and enable prompt diagnosis
and treatment of affected siblings.
† In combined pituitary deficits, phenotypes can be
highly variable, and can evolve, therefore careful
ongoing assessment is required in these patients.
† Family screening in cases with IGSF1 or TRHR
mutations is important to identify apparently healthy
relatives with hitherto undiagnosed central hypothyr-
oidism who may benefit from levothyroxine treatment.
† Levothyroxine is an effective treatment for CCH; fT4
levels should be maintained in the mid-upper part of
the normal range.
† Cortisol deficiency should be corrected before
initiation of levothyroxine and the clinician should
be alert to the fact that other hormone replacements
(GH, oestrogen) may alter levothyroxine requirements.Declaration of interest
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